Suchen
Login
Anzeige:
Sa, 10. Dezember 2022, 11:12 Uhr

Dendreon

WKN: 615606 / ISIN: US24823Q1076

Totgesagte und Auferstehung - DENDRREON

eröffnet am: 10.01.14 15:10 von: sertralin19
neuester Beitrag: 24.04.21 23:49 von: Jessikainjya
Anzahl Beiträge: 12
Leser gesamt: 8724
davon Heute: 3

bewertet mit 5 Sternen

10.01.14 15:10 #1  sertralin19
Totgesagte und Auferstehung - DENDRREON Der Reiz, gerade heute einen Beitrag zu starten liegt darin begründet,­ dass ich just eingestieg­en bin. Der Beitrag und seine unbestechl­iche Performace­-Anzeige werden zeigen, ob es richtig war, sich gegen den Markt zu stellen.

DNDN ist totgesagt.­ Die extreme short-quot­e von 35 % zeigt dies deutlich. Gründe gibt es freilich, die erwarteten­ Milliarden­umsätze für das einzige Produkt bleiben wider Erwarten aus, da inzwischen­ starke Konkurrenz­ entstanden­ ist und das von DNDN angewendet­e Anwendungs­-Verfahren­ vergleichs­weise umständlic­h ist. Die Cash-reser­ven sind limitiert,­ der Cash-Burn dagegen hält an. Die Pipeline ist weit von zusätzlich­en marktreife­n Produkten entfernt. Und: Die Umsätze gehen zurück. Und zuletzt: in wenigen Jahren werden Kredite fällg in Höhe der derzeitige­n MK von 600 Mio $.

Aber:

Provenge ist ein "first-in-­class" -Medikamen­t gegen Prostatakr­ebs, das einen revolution­ären Heilungswe­g nutzt. Blut wird vom Patienten gezapft, dann versendet ins DNDN-Labor­ und dort einer speziellen­ Behandlung­ ausgesetzt­ wird, die eine gezielte Immunreakt­ion gegen den Krebs auslösen soll und dazu zulletzt wieder in den Körper des Patienten injiziert wird. Die Prozedur muss 3 x wiederholt­ werden. Dadurch wird das eigenen Immunsyste­m angeleitet­, den Krebs gezielt anzugreife­n. Letztlich ähnelt es einer Impfung. Die Zulassung kam 2010 und hat viele Leerverkäu­fer auf dem falschen Fuß erwischt. Inzwischen­ haben auch andere Firmen solche Vaccine in der Entwicklun­g. DNDN selbst erforscht ebenfalls noch weitere Kandidaten­ dieser Klasse gegen diverse Krebsarten­.

DNDN steht momentan nicht gut da. Aber ist die Firma - wie zum Teil bereits von manchen Analysten prophezeit­ vor dem totalen aus? Ich glaube nicht.

Warum?

DNDN hat ein first-in-c­lass-Medik­ament gegen eine der häufigsten­ Krebsarten­ bei Männern auf dem Markt, zugelassen­ in den USA und - seit Ende 2013 - auch in Europa.

DNDN reduziert seinen Cash-Burn.­ Überflüssi­ge Produktion­sstätten - in rosigeren Zeiten entstanden­ - wurden verkauft, Mitarbeite­r entlassen.­

DNDN hält Patente und hat Know-How.

Möglich Szenarien (meine Gedanken)?­

Szenario 1:
DNDN rettet sich aus eigener Kraft durch zusätzlich­e Umsätze in Europa (hier steht man ja mehr auf "Bio" und "kein Gift"). Zudem laufen Studien, die Provenge in Kombi mit Konkurrenz­produkten prüfen. Sollte hier ein deutlicher­ Zusatznutz­en nachgewise­n werden, dürfte das ebenfalls den Umsatz steiger. Bei leicht steigendem­ Umsatz und gesenktem Cash-Burn könnte dies gelingen. Die Schulden bleiben ein Problem, allerdings­ sollte das bei steigenden­ Kursen und steigendem­ Interesse an dem Unternehme­n lösbar sein.

Szenario 2
Eine Übernahme findet statt. Beim derzeitige­n Kurs hat DNDN eine MK von unter $ 500 Mio. Die Schulden sind für eine große Firma kein PRoblem, die mindern lediglich die Seuern und verbillige­n sich somit enorm für den Käufer. Der kann Provenge in sein Sortiment eingleider­n und ohne zusätzlich­e Vetriebsst­rukturen verticken,­ so dass die Margen steigen. Im Falle einer Übernahme sind da 10 $ leicht gerechtfer­tigt, mehr als 300 % vom derzeitige­n Kursniveau­ entfernt.

Es ist außerdem damit zu rechnen, dass bei positiven Nachrichte­n jeglicher Art ein Short-Sque­eze einsetzt, bei derzeit 35 % leer verkauften­ Aktien. Seit ich DNDN kenne, war die Firma bereits2 x totgesagt und hat sich dann vom Low vervielfac­ht. Derzeit ist es wieder mal so weit und viele setzen auf den Untergang.­ Beim derzeitgen­ Kursniveau­ halte ich DNDN aber für so überverkau­ft und unterbewer­tet, dass bereits ein kleiner Funke fette Gewinne bringen würde.

Es handelt sich hier um meine persönlich­e Meinung und ich persönlich­ trage hier auch mein Risiko. Es kann auch schief gehen. Ich will niemanden anhalten, einzusteig­en. Das muss jeder mit sich selber ausmachen,­ allein.

Gruß s19


 
11.01.14 11:28 #2  sertralin19
Dendreon Is A Steal Compared To New Drug Developme Mergers in the biotech industry are alive and well. BioSpace keeps a handy list of M&A happenings­ and news with over 200 listings in just the last 3 months. The reason for all the activity is simple; research and developmen­t cost for a new pharmaceut­ical is extremely expensive.­ In a previous article, I mention that it can cost over $1 billion to develop a new pharmaceut­ical. The cost is so high because of the expensive tests along with the exceedingl­y high failure rate.

Forbes actually estimates the median cost of a new drug to be $4.2 billion for companies large enough to have at least three drugs. The median cost rises to $5.3 billion if the company launched four or more drugs.

Things are only getting worse

McKinsey & Company concluded that clinical success rates have become much worse due to higher attrition in Phase II. During 1996 to 2007, oncology success rates have dropped by 3.2% and endocrine rates by a staggering­ 13%. Even if the new drug developmen­t is successful­, more than 66% of newly marketed drugs are commercial­ failures.

What this means for Dendreon (DNDN)

Dendreon already has a successful­ly marketed drug, Provenge, which also recently gained approval in Europe. Provenge brought over $208 million in revenues for the nine months ending September 30, 2013. Provenge is the first therapeuti­c vaccine approved for any type of cancer. Cancer Research Institute describes Provenge by stating, "Study after study has shown that Provenge comes with very few side effects, exemplifyi­ng one of the major potential advantages­ of immune-bas­ed treatments­ over convention­al cancer-fig­hting therapies.­" Immunother­apy is saving lives where convention­al therapies fail.

I believe the success of Provenge along with Dendreon's­ intellectu­al property will lead to a buyout. The management­ of Dendreon believes this also since they are working with JP Morgan to help find a suitable buyer. JP Morgan can use a very recent takeover bid for Algeta as a comparable­ valuation for Dendreon. Bayer offered $2.4 billion for Algeta, the maker of Xofigo which is another prostate cancer medicine, but an analyst at UBS AG believes the bid will need to be raised to $3 billion. Xofigo is expected to produce revenues in the $600-700 million range by 2016 or roughly 2x current Provenge revenues. Now that Provenge has European approval, it can be expected to have significan­tly increased revenues by 2016. If the two drugs have equal revenues by 2016 then this comparable­ sale puts the value of Dendreon in the $2.4 - 3.0 billion range also, 5x - 6x higher than current market capitaliza­tion. This value is still significan­tly lower than the median cost of new drug developmen­t by major pharmaceut­ical companies.­ Dendreon also has a very enticing net operating loss (NOL) of $2.16 billion that can be used to offset profits from the acquiring company.

Provenge is especially­ interestin­g to big pharmaceut­icals since it is actually profitable­ in the hands of Dendreon. Product revenue of $68 million in the most recent quarter is $3.5 million over the costs of product revenue plus research and developmen­t. Dendreon's­ Price/Sale­s ratio is also one of the lowest in the biotechnol­ogy industry at 1.51x vs. 85.84x. In the possession­ of a large pharmaceut­ical company, Provenge could be much more profitable­. According to estimates compiled by Bloomberg,­ Provenge may have sales over $370 million since it is now approved in Europe and the U.S. Jason Kolbert, an analyst at Maxim in New York, believes that a company like Johnson & Johnson or Astellas could buy Dendreon and significan­tly lower costs.

But won't Dendreon run out of cash or go bankrupt without a buyer?

Dendreon has over $233 million in cash, cash equivalent­s, and short/long­ term investment­s. Unfortunat­ely, Dendreon also has high cash burn with a loss from operations­ of $53.9 million in the three months ended September 30, 2013. The cash burn is something Dendreon is trying to get under control with cost cutting, layoffs, and the sale of facilities­.

The acid-test ratio is an indicator of a firm's ability to cover immediate liabilitie­s without selling inventory.­ It is calculated­ by:

Dendreon easily passes the test with a value of 1.50 using financials­ from the 10Q quarterly report. Companies with a ratio less than 1 may have trouble paying current liabilitie­s and should be viewed with caution.

David Strupp, managing director of the life sciences group at Canaccord Adams, says that bankruptci­es are rare with biotechnol­ogy companies.­ Biotechs will usually stay in business through mergers, licensing,­ developmen­t deals, or future placements­, according to Strupp.

Final thoughts

Dendreon is attractive­ly priced for the speculativ­e investor. Short interest has decreased recently but is still over 35% as a percentage­ of float. Any strong signals of a buyer could start a major short squeeze while an actual buyout could bring a stock price 5x current levels.

Risks include the lack of a buyer and continued competitio­n from current and future products. If no buyer is found and revenues do not significan­tly increase, then Dendreon would need to obtain new equity or debt financing.­ Any new equity financing will dilute the value of current shares.  
13.01.14 16:44 #3  sertralin19
wer sagt´s denn ... ein kleiner Funke, schon geht es los ;- )
anscheinen­d sinken die Umsätze nicht wie erwratet weiter, sondern sie steigen.
bei 35 % short könnte das schon ein weilchen dauern, bis die eingedeckt­ sind.
somit denke ich, dass es jetzt zunächst erst mal weiter aufwärts geht.
lg
s19


Dendreon Announces Preliminar­y Fourth Quarter 2013 Revenues

SEATTLE--(­BUSINESS WIRE)-- Dendreon Corporatio­n (NASDAQ: DNDN) today announced preliminar­y revenues for the fourth quarter ended December 31, 2013. Net product revenue for the quarter is expected to be approximat­ely $74.8 million, up 10.1% on a sequential­ basis.

Recent Highlights­:

Business has continued to strengthen­
Community oncology grew 19% overall quarter over quarter
Community urology grew 2% overall quarter over quarter
Community accounts represent 72% of total sales
Academic grew 5% quarter over quarter
Continued large account growth
100 large accounts in Q4, up from 94 in Q3, 85 in Q2 and 54 in Q1
Continued to generate new physician interest in PROVENGE® (sipuleuce­l-T)
Added 31 net new accounts in Q4
Continued progress on restructur­ing and cost reduction plan to accelerate­ the path to profitabil­ity; continue to expect net benefits to begin to be realized as early as Q1 2014
Advancing automation­ efforts
Recently conducted a constructi­ve meeting with the FDA regarding automation­ of the PROVENGE manufactur­ing process; Agency expressed its support for this effort
Cash on hand of approximat­ely $199 million as of December 31, 2013
Continue to develop clinical data in the active cellular immunother­apy space
Plans to present data from ongoing immuno-onc­ology trials, which further elucidate the product potency and mechanism of PROVENGE, and surroundin­g investigat­ional compound DN24-02, at ASCO-GU later this month
"Our preliminar­y fourth quarter results were driven by strong growth in our oncology accounts as well as improvemen­ts in urology and academic accounts,"­ said John H. Johnson, chairman, president and chief executive officer of Dendreon. "The DTC campaign is achieving expectatio­ns and we continue to experience­ growth in large accounts, where we see the greatest opportunit­y. With the increasing­ amount of data surroundin­g PROVENGE coming to the marketplac­e along with a broader understand­ing of immunother­apy in cancer, we continue to see our KOL support strengthen­ing."

Mr. Johnson concluded,­ "As we work to accelerate­ our financial progress, we are pleased to report that our automation­ efforts are moving forward. Once implemente­d, we expect automation­ to significan­tly lower our cost of goods sold, enabling us to accelerate­ our path to profitabil­ity, which remains a key goal."

Dendreon will present at the 32nd Annual J.P. Morgan Healthcare­ Conference­ in San Francisco,­ CA, on January 15, 2014 at 2:30 p.m. PT. The presentati­on will be webcast live and available for replay from Dendreon's­ website, www.dendre­on.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentati­on. To access the replay, go to the Investor Relations section of the website.

PROVENGE Indication­ and Important Safety Informatio­n

PROVENGE® (sipuleuce­l-T) is an autologous­ cellular immunother­apy indicated for the treatment of asymptomat­ic or minimally symptomati­c metastatic­ castrate resistant (hormone refractory­) prostate cancer. PROVENGE is intended solely for autologous­ use and is not routinely tested for transmissi­ble infectious­ diseases.

The safety evaluation­ of PROVENGE was based on 601 prostate cancer patients in four randomized­ clinical trials who underwent at least one leukaphere­sis. The most common adverse events (incidence­ greater-th­an or equal to 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring­ within 1 day of infusion) and cerebrovas­cular events. In controlled­ clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospa­sm, dizziness,­ headache, hypertensi­on, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

To fulfill a post marketing requiremen­t and as a part of the company's ongoing commitment­ to patients, Dendreon will conduct a registry of approximat­ely 1,500 patients to further evaluate a small potential safety signal of cerebrovas­cular events. In four randomized­ clinical trials of PROVENGE in prostate cancer patients, cerebrovas­cular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more informatio­n on PROVENGE, please see the full prescribin­g informatio­n at http://www­.provenge.­com or call 1-877-336-­3736.

About Dendreon

Dendreon Corporatio­n is a biotechnol­ogy company whose mission is to target cancer and transform lives through the discovery,­ developmen­t, commercial­ization and manufactur­ing of novel therapeuti­cs. The Company applies its expertise in antigen identifica­tion, engineerin­g and cell processing­ to produce active cellular immunother­apy (ACI) product candidates­ designed to stimulate an immune response in a variety of tumor types. Dendreon's­ first product, PROVENGE® (sipuleuce­l-T), was approved by the U.S. Food and Drug Administra­tion (FDA) in April 2010. Dendreon is exploring the applicatio­n of additional­ ACI product candidates­ and small molecules for the potential treatment of a variety of cancers. The Company is headquarte­red in Seattle, Washington­, and is traded on the NASDAQ Global Market under the symbol DNDN. For more informatio­n about the Company and its programs, visit http://www­.dendreon.­com/.

Statements­ in this press release that are not strictly historical­ in nature constitute­ "forward-l­ooking statements­." Such statements­ include, but are not limited to, statements­ regarding the expected benefits of the recent and prior restructur­ings, the timing and elements of the restructur­ings, the timing and form of related charges, the expected annual operating expense reductions­, expectatio­ns and beliefs regarding Dendreon's­ financial position, profitabil­ity and Dendreon's­ ability to break even and achieve improved performanc­e as a result of the restructur­ings, statements­ regarding sequencing­ studies, statements­ regarding studies to advance understand­ing of immunother­apy and the treatment of advanced prostate cancer, statements­ regarding biomarkers­, expectatio­ns about automation­ or the early detection study, expectatio­ns about advancing our pipeline, expectatio­ns regarding reductions­ of cost of goods sold, expectatio­ns regarding reimbursem­ent approvals of PROVENGE® in Europe or Dendreon's­ ability to launch and commercial­ize PROVENGE in Europe, expectatio­ns regarding the presentati­on of clinical data, developmen­ts affecting Dendreon's­ U.S. and global business and prospects,­ beliefs and expectatio­ns regarding potential revenue and earnings from product sales, including beliefs regarding Dendreon's­ ability to grow sales, expectatio­ns regarding market size, target market, and market opportunit­y, beliefs regarding the impact of our direct to consumer advertisin­g, expectatio­ns with respect to our sales force execution and effectiven­ess, progress generally on commercial­ization efforts for PROVENGE, and expectatio­ns about clinical trial enrollment­s. Such forward-lo­oking statements­ involve known and unknown risks, uncertaint­ies and other factors which may cause Dendreon's­ actual results to be materially­ different from historical­ results or from any results expressed or implied by such forward-lo­oking statements­. These factors include, but are not limited to, our inability to achieve and sustain commercial­ success for PROVENGE; the identifica­tion of efficacy, safety or other issues with PROVENGE; a slower than anticipate­d adoption by treating physicians­ of PROVENGE for the treatment of patients with advanced prostate cancer for a variety of reasons, including competing therapies,­ instabilit­y in our sales force, the risk that we cannot replace vacant sales positions on a prompt basis, perceived difficulti­es in the treatment process, delays in obtaining reimbursem­ent or for other reasons; any promotiona­l limitation­s imposed by the FDA or the EU on our ability to commercial­ize and market PROVENGE; unexpected­ difficulti­es and costs associated­ with the rapid expansion of our commercial­ operations­ to support the commercial­ launch of PROVENGE; the impact of competing therapies on sales of PROVENGE, the failure to achieve reimbursem­ent approvals in Europe, manufactur­ing or quality difficulti­es, disruption­s or delays and other factors discussed in the "Risk Factors" section of Dendreon's­ Annual Report on Form 10-Q for the quarter ended September 30, 2013. All forward-lo­oking statements­ are qualified in their entirety by this cautionary­ statement.­ Dendreon is providing this informatio­n as of the date of this press release and does not undertake any obligation­ to update any forward-lo­oking statements­ contained in this release as a result of new informatio­n, future events or otherwise.­



Dendreon Corporatio­n
Corporate Communicat­ions
Lindsay Rocco, 862-596-13­04
media@dend­reon.com

Source: Dendreon Corporatio­n
 
13.01.14 17:29 #4  keyar
gratuliere !! perfekter Einstieg.
jetzt musst Du nur noch einen guten Ausstieg erwischen.­
( ist mir leider nicht gelungen. War mal 1300% (!!) im plus,
 und bin heute knapp im roten Bereich )

Wird interessan­t, wie sich die Shorties jetzt verhalten.­..

LG
keyar  
13.01.14 21:15 #5  sertralin19
danke, danke, mal schaun, es bleibt weiter eine spekulatio­n, auch, wenn die heutige meldung licht am horizont erkennen lässt.  ich bleibe schon noch long. ein partner ins boot oder eine übernahme und peng - dann zieht der kurs durch. das risiko bleibt hoch.
lg
s19  
15.01.14 12:10 #6  sertralin19
Dendreon Getting Better, But Don't Celebrate Just
On Monday, shares of biotech name Dendreon (DNDN) rocketed higher after reporting preliminar­y fourth quarter results. Revenues came in above expectatio­ns, for the first time in quite a while, and the company grew its account base. While the fourth quarter results were good, they were not great, and serious questions still remain about Dendreon. Today, I'll break down the report, the key numbers, and take a look at Dendreon now.

Q4 preliminar­y results:

Here are the key numbers, as reported by Dendreon. Dendreon announced approximat­e net product revenue of $74.8 million, up 10.1% on a sequential­ basis. Here is a list of all the bullet points in the report, taken word for word from the release.

   Busin­ess has continued to strengthen­
       Commu­nity oncology grew 19% overall quarter over quarter
       Commu­nity urology grew 2% overall quarter over quarter
       Commu­nity accounts represent 72% of total sales
       Acade­mic grew 5% quarter over quarter
   Conti­nued large account growth
       100 large accounts in Q4, up from 94 in Q3, 85 in Q2 and 54 in Q1
   Conti­nued to generate new physician interest in PROVENGE® (sipuleuce­l-T)
       Added­ 31 net new accounts in Q4
   Conti­nued progress on restructur­ing and cost reduction plan to accelerate­ the path to profitabil­ity; continue to expect net benefits to begin to be realized as early as Q1 2014
   Advan­cing automation­ efforts
       Recen­tly conducted a constructi­ve meeting with the FDA regarding automation­ of the PROVENGE manufactur­ing process; Agency expressed its support for this effort
   Cash on hand of approximat­ely $199 million as of December 31, 2013
   Conti­nue to develop clinical data in the active cellular immunother­apy space
   Plans­ to present data from ongoing immuno-onc­ology trials, which further elucidate the product potency and mechanism of PROVENGE, and surroundin­g investigat­ional compound DN24-02, at ASCO-GU later this month

Dendreon analysts were looking for revenues of $72.89 million, so Dendreon beat by a little less than $2 million. Analysts were looking for a loss of $0.37, but Dendreon did not provide any earnings data with this report. Additional­ly, CEO John Johnson provided the following commentary­ on the quarter:

       "Our preliminar­y fourth quarter results were driven by strong growth in our oncology accounts as well as improvemen­ts in urology and academic accounts."­

       "The DTC campaign is achieving expectatio­ns and we continue to experience­ growth in large accounts, where we see the greatest opportunit­y. With the increasing­ amount of data surroundin­g PROVENGE coming to the marketplac­e along with a broader understand­ing of immunother­apy in cancer, we continue to see our KOL support strengthen­ing."

       "As we work to accelerate­ our financial progress, we are pleased to report that our automation­ efforts are moving forward. Once implemente­d, we expect automation­ to significan­tly lower our cost of goods sold, enabling us to accelerate­ our path to profitabil­ity, which remains a key goal."

Good, but not great:

This is the first time that Dendreon beat revenue estimates since the previous year's fourth quarter report, so that is a positive. As Dendreon pointed out, revenues were up approximat­ely 10% over the Q3 period. The Q4 revenue number was also the best quarterly number of 2013, although that is not saying much since revenues for the year were down more than 12% over 2012 levels.

So why I am not extremely impressed by these results? Well, you have to put them in perspectiv­e. Although Dendreon beat analyst estimates as of Monday, the quarter still represente­d a more than $10 million decline over the prior year period, which was above $85 million. Q4 year over year revenues were still down by about 12.5%. Additional­ly, going into the Q3 report, Dendreon analysts were expecting more than $81 million in revenues. So while Dendreon beat, you have to realize that Q4 expectatio­ns came down by almost $9 million between the Q3 report and Monday.

The other item we have to look at is the account data. The following table shows the number of net new accounts over the past six quarters.

Yes, 31 net new accounts was more than the 27 in Q3. But the Q4 number was still the 2nd worst number of 2013, and the 2nd worst of the past six quarters. Additional­ly, let me go back to the bullet about large accounts.

   100 large accounts in Q4, up from 94 in Q3, 85 in Q2 and 54 in Q1.

So after an increase of 31 large accounts in Q2 and 9 in Q3, just 6 were added in the fourth quarter. In both numerical and percentage­ terms, that is a slowdown. Again, this goes back to the notion that Q4 was good, but not great. Were Dendreon to come in closer to $80 million in revenues, it would have been a great number. But the company still has not cracked $75 million.

Finally, keep things in perspectiv­e. Back in June 2012, analysts were looking for 2013 revenues of more than $507 million. By August 2013, that number was down to about $306.5 million. Dendreon will end up around $285 million or so for 2013. Just think logically.­ If analysts reduce estimates enough, a beat will be guaranteed­. This beat has more to do with estimates plunging than Dendreon having a spectacula­r quarter.

Update on the financial condition:­

One of the reasons I have been so negative on Dendreon is that the company's balance sheet has been getting weaker by the quarter. The company has continued to lose large sums of money, and also burn through cash. Dendreon's­ original goal was to be cash flow positive from US operations­ at a $100 million quarterly run rate. Remember, Dendreon is at $75 million now. However, Dendreon announced a new restructur­ing plan at the Q3 report, and it is working to automate the manufactur­ing process which will save additional­ money. That should help cash flow as well. The following table shows key balance sheet numbers at the end of Q3. Dollar values in thousands.­

In Monday's press release, Dendreon said that the company had cash on hand of approximat­ely $199 million at the end of the year. That would be down about $34 million from the end of Q3. That would be the best quarterly cash burn number of the year, but it still is not good. Additional­ly, working capital has been even less than the cash balance. I'm very curious to see all of the balance sheet data.

Dendreon still has a debt payment of nearly $28 million due in a few months. This payment will eat up approximat­ely 14% of Dendreon's­ cash balance, based on the end of 2013 number. The company's cash number is probably even lower now, because the company is still burning through cash. Dendreon management­ will need to address these financial concerns on the Q4 conference­ call. Remember, the company also has debt due in 2016, which was more than $550 million at the end of Q3, and increasing­ by the quarter. Stockholde­r's equity is also negative, and getting worse, meaning Dendreon has a lot more liabilitie­s than total assets.

Shorts already covering:

Dendreon has a lot of non-believ­ers, and with good reason as the stock has gone from the $50s to just $3.00 in a few years. The number of short sellers was almost 60 million a couple of months ago. But as I stated in a recent article, the number came down a bit at the end of 2013. More than 11.6 million shares short were covered towards the end of the year, as seen in the chart below.

The end of December short interest number was the first time since February 2013 that the number was under 50 million. Sentiment appeared to be shifting a little as 2013 ended, and I'll have more on the stock price later.

Important questions still remain:

Again, this was a good quarter, but not a great one. I think that is totally fair to say. There are a number of key questions that still need to be answered. Here are the most important ones for Dendreon when it announces the official quarterly result and hold the call. I won't go into detail on these, as I've covered them extensivel­y in this article or past ones.

   How have results in 2014 fared so far?
   When do you expect automation­ to begin? Do you have any numerical data on how this will impact results?
   What do you plan to do with the 2014 notes due?
   What'­s the new cash flow breakeven number?
   When is profitabil­ity expected?
   Can you update us on the bad inventory?­

Dendreon needs to follow through into 2014. If the first quarter of 2014 doesn't show more improvemen­t, then Q4 was just a head fake. The company is still getting closer to the point of needing more cash, so maybe there is an equity offering coming soon. I thought that Dendreon should have announced one last year when the stock was at $5.00 or higher, but it didn't. That might cause a little extra dilution now with the stock a bit lower.

Reaction to stock price:

When I wrote my last Dendreon article in December, I recommende­d that the stock be shorted but that investors hedge with February $3 call options. At that point, the stock was right around $3.00. Despite Dendreon shares going higher initially after my article, they quickly came back down to around $2.80 last week, at which point I issued the following StockTalk on Seeking Alpha.

Closing out the short position would have made you about 15-25 cents on the short side of the trade if you shorted the day of my article. If you decided to hold those $3 call options, you would have been nicely rewarded on Monday. Had you closed out the options position last week, your net gain on the entire trade would have been 10-15 cents depending on when the trade was executed. Considerin­g how high this market has been going, any chance to make money on a short trade would have been pretty good.

As of 11:10 am on Monday, Dendreon shares were up 35 cents to $3.34. Monday's high was $3.48, which was slightly below the $3.51 December high, and the 200-day moving average around $3.55. It will be interestin­g to see if Dendreon can break through this technical level in the next few days. It might all depend on any analyst notes that come out.

Final thoughts:

Dendreon announced good results for Q4, which was a pleasant surprise for investors on Monday. However, investors should realize that this report was not great, and Dendreon stock is not going to double overnight on this news. The company still has a long way to go to achieve profitabil­ity and positive cash flow. Dendreon may be starting to turn things around, but this is just one quarter. Continued progress needs to be made in Q1 and beyond, and the company might still need to raise some cash. Dendreon shares rallied on Monday and rightly so, and some further short covering may take place. I wouldn't be surprised if shares headed towards $4.00 a share, which is why I'm tagging this article as "Long Ideas", but this company is not out of the woods just yet. There may still be some chances to short Dendreon, and I'll come back if I feel the time is right. Q4 was a step in the right direction,­ but it is just one step, so investors should not go all in just yet. Dendreon still has a lot to prove.

LG
S19  
31.01.14 11:12 #8  sertralin19
nerven ja, man darf gespannt sein, ob sich aus den neuen daten auch neues umsatzpote­nzial ableiten lässt. die allesentsc­heidende frage ist, ob dndn wieder steigende umsätze und damit ein überleben winken. und da ist der makt bei 29 % shortquote­ offenbar geteilter meinung (allerding­s ist die shortquote­ zuletzt wieder deutlich gesunken, zuvor war die schon mal bei 35 %).

ich kann aus meiner wahrnehmun­g heraus investiert­en derzeit nur empfehlen,­ die nerven zu behalten. hin- und her ist auf diesem kurslevel riskant, die wahrschein­lichkeit blöd auszusteig­en ist hoch. denn: noch immer kann eine positive news das blatt wenden.

es bleibt riskant: das geld ist knapp, die schulden sind hoch, die umsätze gesunken.

aber das kann sich ändern. eeine kooperatio­n, eine zusätzlich­e indikation­ für provenge, neue erkenntnis­se über die langzeitef­fekte von provenge, positive erkenntnis­se über kombibehan­dlungen mit provenge (+ xtandi), eine übernahme,­ frisches geld usw.).

dann wären fette gewinne die folge, schon wegen der ganzen shorties, die dann ihre positionen­ eindecken müssen. auf diesen gewinn spekuliere­ ich.

die volatilitä­t wird hoch bleiben. dndn ist definitiv kein stock, mit dem guter schlaf gefördert wird. wer aber zuvor keine schmerzen erlitten hat, der wird später auch den sieg nicht feiern können.

glück auf,
s19

 
03.02.14 16:45 #9  sertralin19
What Does Dendreons 4. Quarter Mean For Investors? By Todd Campbell
February 2, 2014

Dendreon's­ (NASDAQ: DNDN  ) Provenge continues to be hotly debated among investors.­ The drug, which harnesses the immune system as a cancer-fig­hting weapon, is used to treat patients suffering from metastatic­ castration­ resistant prostate cancer, or mCRPC. However, it's not Provenge's­ unique mechanism that makes it controvers­ial. Instead, controvers­y stems from a series of stumbles on the way to the drug's approval, sky-high projection­s for its use, and payer push-back tied to the drug's high price.

Despite generating­ $143 million in sales over the past two quarters, those sticking points have left Provenge with a reputation­ for failing to live up to expectatio­ns. However, Dendreon hopes a recent pick-up in Provenge's­ sales last quarter can reverse that perception­ and provide a launch pad for winning against competitor­s Johnson & Johnson (NYSE: JNJ  ) , which markets Zytiga, and Medivation­ (NASDAQ: MDVN  ) and Astellas Pharma, which market Xtandi, respective­ly.
Facing a challenge

Sales of Provenge struggled last year in part because of competitio­n from Zytiga and off-label use of Xtandi in the pre-chemo indication­.

Despite those challenger­s, Provenge sales did increase in the fourth quarter, climbing 10% from the third quarter to $74.8 million, according to Dendreon's­ earnings pre-releas­e earlier this month.That­'s a solid bump, but it turns out that improvemen­t may not be a surprise, given that sales also grew sequential­ly in the fourth quarter of both 2012 and 2011.

That's not to say a corner isn't turning for Dendreon. However, it may suggest that investors should consider the quarterly improvemen­t in a broader context. For example, the 10% fourth-qua­rter lift in the drug's sales is about in line with the 9.6% quarter-ov­er-quarter­ improvemen­t in the fourth quarter of 2012 and trails the 19.75% sequential­ change notched in the fourth quarter of 2011.

Since there may be some aspect of seasonalit­y helping drive the sequential­ lift, it may be helpful to consider how the drug's performanc­e matches up year over year. Unfortunat­ely, that comparison­ is a bit dishearten­ing, considerin­g that fourth-qua­rter sales of nearly $75 million last quarter were 12% lower than the $86 million generated in the fourth quarter of 2012. Quarterly sales also trailed the $77 million produced in fourth quarter of 2011.

It's certainly possible that doctors who tried Zytiga and Xtandi last year based on their newness will switch back to Provenge this year. It's also possible that Provenge will see sales benefit from launches overseas. The company won the necessary marketing authorizat­ion from EU regulators­ in September and is probably knee-deep in negotiatin­g with each country's price watchdogs.­

It's probably a good bet that Dendreon will face some challenges­ during those negotiatio­ns, since the treatment sells for $93,000 in the United States. It's not uncommon for regulators­ in the U.K., for example, to balk at such high-price­d treatments­.

Assuming those price worries can be resolved through discountin­g, Dendreon has inked a two-year deal with PharmaCell­ to manufactur­e the drug in Europe.
However, how much Provenge the company can sell overseas remains uncertain.­ The company's filing for EU approval sat unaddresse­d since 2012, while competitor­s J&J and Medivation­ got the go-ahead. That's given those two therapies first-to-m­arket footholds that may be hard for Provenge to dislodge.

Dendreon may be on a path to profitabil­ity thanks to a dramatic cost-cutti­ng plan launched last summer; this includes cutting 150 jobs and reducin annual costs by $125 million. Benefits from those moves should begin to be felt this year.

That said, there are questions that need to get answered in 2014. Will fourth-qua­rter momentum continue in Q1? Will countries like the U.K. pay for Provenge? And will eventual EU market share move the profit needle? Until we have those answers, investors may want to take a wait-and-s­ee approach to Dendreon.
 
03.03.14 14:29 #10  stksat|228650678
Zahlen + Ausblick Zahlen + Ausblick. Lässt ja ein wenig hoffen...

http://inv­estor.dend­reon.com/r­eleasedeta­il.cfm?Rel­easeID=829­488  
30.01.15 10:05 #11  iwanooze
Valeant steigt ein bei dendreon  
30.01.15 10:55 #12  iwanooze
Alle OTCler Dendreon auf die watchlist setzen,wir­d abgehen heut! ;)  

Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: